Oscillatory Positive Expiratory Pressure Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, Segmented By Type, By Application, By Region & Competition, 2021-2031F

The Global Oscillatory Positive Expiratory Pressure (OPEP) Market is projected to expand from USD 2.89 Billion in 2025 to USD 4.28 Billion by 2031, demonstrating a compound annual growth rate (CAGR) of 6.76%. OPEP devices are non-invasive medical solutions designed to aid mucus clearance through resistance and vibrations during exhalation, effectively loosening bronchial secretions. This market growth is primarily fueled by the increasing worldwide incidence of chronic respiratory conditions like cystic fibrosis, bronchiectasis, and Chronic Obstructive Pulmonary Disease (COPD), along with a growing elderly population prone to declining lung function. These factors represent a fundamental, long-term healthcare need for managing diseases and preventing respiratory complications in home settings, distinct from short-term market fluctuations.

However, a significant obstacle to market expansion is the inconsistent reimbursement coverage across various regions, which limits patient access to these crucial therapies. This financial hurdle is particularly problematic given the vast number of patients requiring effective airway clearance. The World Health Organization reported that in 2025, 81.7 million people in the WHO European Region alone were affected by chronic respiratory diseases, highlighting the substantial burden OPEP manufacturers must address amidst complex regulatory and financial environments.

Market Driver

The escalating global prevalence of Chronic Obstructive Pulmonary Disease (COPD) and asthma is the primary driver for the Global Oscillatory Positive Expiratory Pressure Market, creating a consistent need for effective airway clearance. The chronic nature of these respiratory illnesses necessitates regular mucus mobilization to prevent severe flare-ups and hospitalizations. The Centers for Disease Control and Prevention reported in May 2025 that the age-adjusted prevalence of diagnosed COPD in adults in the U.S. was 3.8% in 2023. This clinical burden is exacerbated by environmental hazards that accelerate lung function decline; the American Lung Association noted in April 2025 that 156.1 million Americans lived in areas with unhealthy air pollution levels, thereby increasing the population susceptible to respiratory issues requiring non-pharmacological interventions.

A second significant driver is technological advancements in portable and gravity-independent OPEP device designs, which notably improve patient adherence compared to traditional physiotherapy. Modern OPEP devices are now compact and operable in any position, allowing patients greater mobility during therapy-a key factor for widespread home-care adoption. This emphasis on user-centric design is transforming market competition, with manufacturers focusing on efficacy and ease of use to gain market share. The industry's success in meeting these standards is evidenced by Monaghan Medical Corporation's 10th win in 11 years of the '2025 AARC Zenith Award' in December 2025, highlighting the critical importance of reliable, innovative respiratory technologies. Such innovations distinguish premium devices, fostering market growth by ensuring consistent therapy outside clinical settings.

Market Challenge

Inconsistent reimbursement coverage across different regions poses a significant economic impediment to the Global Oscillatory Positive Expiratory Pressure Market's expansion. Despite the essential role of OPEP devices in airway clearance, varied healthcare policies frequently lead to substantial out-of-pocket costs for patients, severely reducing device adoption rates. This financial strain is especially impactful for the primary user base, which often includes elderly individuals or those managing lifelong conditions on fixed incomes. As a result, when patients cannot afford these vital therapies due to coverage gaps, the market struggles to translate high clinical demand into sustainable revenue growth.

This disparity between patient need and purchasing capability restricts the industry's ability to effectively reach its entire potential market. The magnitude of this unmet need is underscored by recent prevalence data: the American Lung Association reported that in 2025, over 35 million people in America were living with chronic lung disease. This statistic highlights the vast patient population requiring ongoing respiratory support, yet potentially facing limited access to OPEP therapy, thereby constraining the market's growth trajectory despite favorable disease prevalence.

Market Trends

The adoption of combined OPEP and nebulizer therapies is emerging as a crucial trend aimed at reducing the substantial daily treatment burden for patients with chronic respiratory conditions. This integrated approach allows for simultaneous mucus clearance and aerosol medication delivery, significantly cutting down on overall therapy time-a vital factor for promoting consistent patient compliance. The technical feasibility of this dual-modality treatment is supported by recent performance data; a June 2024 laboratory study by Trudell Medical International, detailed in their 'Combination Therapy (OPEP and Nebulizer) to Provide Focus to Mucus Clearance' report, showed that combined therapy delivered over 80% of medication in the respirable droplet size range while maintaining a treatment duration similar to OPEP therapy alone. This efficiency ensures effective pharmacological intervention without sacrificing the mechanical benefits of oscillatory pressure, thereby propelling the market towards multi-functional device ecosystems.

Concurrently, the integration of smart digital connectivity for adherence tracking is redefining the competitive landscape by transforming mechanical devices into connected respiratory health platforms. Manufacturers are increasingly focusing on digital therapeutics that monitor usage patterns and offer real-time feedback to tackle the widespread issue of non-adherence in home-care environments. This data-driven shift is validated by improved clinical outcomes linked to connected care; Health Tech World reported in February 2025 that patients using a respiratory digital care plan for four months or longer experienced a 41% increase in their wellness scores. Such significant improvements underscore the growing market value of embedding connectivity into OPEP strategies to ensure measurable, long-term therapeutic success.

Key Market Players

• Monaghan Medical Corporation
• Hill-Rom Holdings, Inc.
• ICU Medical, Inc.
• Respironics, Inc.
• Teleflex Incorporated
• GlaxoSmithKline plc
• Telecare Services, Inc.
• Summit Medical Products, Inc.
• Fisher & Paykel Healthcare Corporation Limited

Report Scope

In this report, the Global Oscillatory Positive Expiratory Pressure Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Oscillatory Positive Expiratory Pressure Market, By Type

• Facemask OPEP Devices
• Mouthpiece OPEP Devices
• Bottle OPEP Devices

Oscillatory Positive Expiratory Pressure Market, By Application

• Asthma
• Atelectasis
• Bronchitis
• Other

Oscillatory Positive Expiratory Pressure Market, By Region

• North America
  • United States
  • Canada
  • Mexico
• Europe
  • France
  • United Kingdom
  • Italy
  • Germany
  • Spain
• Asia Pacific
  • China
  • India
  • Japan
  • Australia
  • South Korea
• South America
  • Brazil
  • Argentina
  • Colombia
• Middle East & Africa
  • South Africa
  • Saudi Arabia
  • UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Oscillatory Positive Expiratory Pressure Market.

Available Customizations:

Global Oscillatory Positive Expiratory Pressure Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

• Detailed analysis and profiling of additional market players (up to five).